TMCnet News
Clinical Research Proves Efficacy of Canine Platelet Enhancement Therapy (C-PET) for Treatment of Osteoarthritis (OA) in DogsPORT WASHINGTON, N.Y. --(Business Wire)-- A randomized, controlled study organized by The Ohio State University and Western University Health Sciences shows efficacy of autologous platelet therapy for treatment of osteoarthritis (OA) in dogs using Pall's Canine Platelet Enhancement Therapy (C-PETTM) kit. The findings of the study, which were published in the November 1, 2013 issue of the Journal of the American Veterinary Medical Association (JAVMA), offer clinical relevance proving that a single intra-articular injection of autologous platelets can significantly improve dogs with OA. 
Pall's C-PET technology is a proven technique for treating canine osteoarthritis. (Photo: Business Wire) The study evaluated 20 client-owned dogs diagnosed with OA in a single joint. The dogs were randomly assigned to either a treatment group or a control group. They weighed from 40 to 140 pounds, included a wide array of breeds, and ranged in age from 1.5 to 8 years. Lameness of each dog was assessed by their owners using the Hudson Visual Analog Scale (HVAS). Pain was evaluated using the University of Pennsylvania's Canine Brief Pain Inventory (CBPI). The objective measurement of function and weight bearing was determined by the "gold standard" force plate measurement of peak vertical force (PVF)1. The results showed dogs that received C-PET platelet injections significantly improved lameness scores, pain scores and PVF after 12 weeks, compared with pre-treatment values. In contrast, control dogs' lameness scores, pain scores and PVF at week 12 were not significantly different from pre-treatment values. C-PET provides a minimally invasive treatment for OA in dogs. It is safe, effective and convenient. The entire procedure requires about 30 minutes, as documented in the study. It is important to note that not all platelet-rich plasma (PRP) preparation techniques are the same. Therefore, the success or failure of a specific PRP product is not necessarily predictive of all PRP preparations. Well-designed, prospective, randomized, blinded (Level 1) clinical studies are needed to carefully and comprehensively investigate the role of the various PRP preparations. Pall's C-PET is the first platelet technique for treating OA in dogs proven through an objective clinical study. For more information on C-PET, please visit www.Pall.com/CPET. About Pall Corporation Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Follow us on Twitter (News - Alert) @PallCorporation or visit www.Pall.com ______________ 1 Force plate and computer analysis system, Kistler Instrument Corp, Amherst, NY. Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131218006455/en/ |
